Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofazimine in Cryptosporidiosis
NCT03341767Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Dec 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clofazimine in cryptosporidiosis (3 arms), sponsored by University of Washington. Primary endpoints: Reduction in Cryptosporidium fecal shedding following Clofazimine administration at 5 days, Pharmacokinetics (area under curve) of Clofazimine at 5 days and 6 more. Started Dec 2017; status: terminated.
02
Drugs
clofazimine
03
Conditions
cryptosporidiosis
Beyond the preview
Go deeper on NCT03341767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341767.